Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Wajeeh Khan

Eli Lilly Pops on GLP-1 Pill Approval. Should You Buy LLY Stock Here?

Eli Lilly (LLY) shares are extending gains on Wednesday after the FDA approved Foundayo — the company’s first once-daily oral GLP-1 for chronic weight management. As investors cheered the pivot to a more convenient, non-injectable alternative for obesity treatment, LLY broke above its 20-day moving average (MA), indicating the upward momentum may sustain in the near-term. 

Despite the headline rally, however, Eli Lilly stock remains down over 10% versus the start of 2026.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.